Developing tests for early detection of aggressive prostate cancer
Administrative Core
This study is working on new urine tests to help find aggressive prostate cancer early by looking at specific genetic markers, so that patients can better understand their risk and make informed choices about their treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10891586 on NIH RePORTER |
What this research studies
This research focuses on creating and improving clinical tests that can detect aggressive prostate cancer at an early stage. The team, consisting of experts from the University of Michigan and Vanderbilt University Medical Center, is working on advanced assays that analyze specific genetic markers associated with prostate cancer. By utilizing urine samples, the tests aim to provide personalized risk assessments for patients, helping them make informed decisions about their treatment options. The project builds on previous successes in biomarker characterization and aims to enhance the accuracy and reliability of prostate cancer diagnostics.
Who could benefit from this research
Good fit: Ideal candidates for this research include men at risk for prostate cancer, particularly those with elevated PSA levels or family histories of the disease.
Not a fit: Patients with non-aggressive prostate cancer or those who have already been diagnosed and treated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate early detection of aggressive prostate cancer, potentially improving treatment outcomes for patients.
How similar studies have performed: Previous research efforts in biomarker characterization for prostate cancer have shown promising results, indicating that this approach has the potential for success.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Chinnaiyan, Arul M — University of Michigan at Ann Arbor
- Study coordinator: Chinnaiyan, Arul M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.